Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the Marketing Authorization of Zynquista (sotagliflozin), developed by Sanofi and Lexicon.

Abbott and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with Abbott’s FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system).

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.

The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.

Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

The U.S. FDA approved Senseonics Holdings’ Premarket Approval application to market the company’s Eversense Continuous Glucose Monitoring System to people with diabetes.

Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.

Novo Nordisk and Glooko announced that the new Cornerstones4Care (C4C) Powered by Glooko app is available to help people more effectively manage their diabetes.